Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05035641 · ClinicalTrials.gov registry record · Phase 2

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

A Phase 2 study of Renal Anemia, sponsored by Kind Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
113
Enrollment target
8
Study locations

NCT05035641 is a Phase 2 study of Renal Anemia that has completed, run by Kind Pharmaceuticals. The registered enrollment target is 113 participants. The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05035641, a Phase 2 study of Renal Anemia, has completed, sponsored by Kind Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
113 participants
Enrollment target
8
Study locations

Study Summary

This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG AND017

Study Locations (8)

California

  • Amicis Research Center - Northridge

Florida

  • Clinical Site Partners - Winter Park

Louisiana

  • Northwest Louisiana Nephrology - Shreveport

Michigan

  • Elite Research Center - Flint

North Carolina

  • Metrolina Nephrology Associates - Charlotte

Tennessee

  • Southeast Renal Research Institute - Chattanooga

Texas

  • Clinical Advancement Center, PLLC - San Antonio

Beijing Municipality

  • Peking University People's Hospital - Beijing

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2021-10-18
Est. Completion 2023-07-24
Phase Phase 2

Sponsor

Kind Pharmaceuticals

3 total trials

What the Registry Record Tells You About NCT05035641

The ClinicalTrials.gov registry entry for NCT05035641 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kind Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Anemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05035641 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Louisiana.

Frequently Asked Questions

What is clinical trial NCT05035641 about?

NCT05035641 is a clinical study titled "A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients". This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients

What is the current status of trial NCT05035641?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2021-10-18. Estimated completion is 2023-07-24.

What conditions does trial NCT05035641 study?

This clinical trial studies the following conditions: Renal Anemia.

What interventions are being tested in trial NCT05035641?

The interventions under investigation include: Placebo (DRUG), AND017 (DRUG).

Who is sponsoring clinical trial NCT05035641?

This trial is sponsored by Kind Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05035641 being conducted?

This trial has 8 study locations across California, Florida, Louisiana, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.